GlassScriptPhysician profile
Divya Singh Malladi
NPI 1952553398
$6,673.51
in general payments reported to CMS, 2019-2025
39 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $385 · 2021: $871 · 2022: $1,122 · 2023: $1,176 · 2024: $1,100 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Education: $69.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.72 |
| Education | $69.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $853.92 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $684.79 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $674.42 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $425.45 | 2021-2025 | |
| Daiichi Sankyo INC. | $327.00 | 2022-2025 | Injectafer |
| Akebia Therapeutics INC | $317.00 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $226.10 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $219.00 | 2021-2024 | Lupkynis |
| Abbott Laboratories | $208.53 | 2020-2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.35 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $203.09 | 2020-2022 | |
| Travere Therapeutics, INC. | $201.10 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $192.99 | 2019-2022 | |
| Ardelyx, INC. | $181.56 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $180.88 | 2022-2025 | Tarpeyo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Malladi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.